SAN DIEGO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower ...

SOMERVILLE, Mass., October 23, 2025 – Cellarity, a biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced the publication of a ...

In the rapidly developing field of spatial biology, researchers are working to expand our understanding of biological processes within their spatial context. Scientists are taking a holistic approach ...

A transcriptome-based evaluation platform for predictive drug efficacy and safety profiling Disease-relevant organoid models for liver, heart, and the blood-brain barrier (BBB) A high-throughput ...

Publication illustrates foundational innovation that has defined the company’s advanced platform integrating high-dimensional transcriptomics and AI predictive modeling for drug discovery Cellarity, a ...

Strategic partnership to deliver transcriptomics-powered, organoid-based preclinical testing for high-impact drug discovery A transcriptome-based evaluation platform for predictive drug efficacy and ...

Multi-omics describes the integration of multiple high-throughput screening technologies based on genomics, proteomics, transcriptomics, single-cell transcriptomics, metabolomics, and more, which all ...

(a) Principal component analysis (PCA) of metabolic profiles of studied provenances at different time points. Note the differences between treatments and time along PC1 and provenance differences on ...